AVAPRO

LOE Approaching

irbesartan

NDAORALTABLET
Approved
Sep 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
46

Mechanism of Action

Angiotensin 2 Receptor Antagonists

Pharmacologic Class:

Angiotensin 2 Receptor Blocker

Clinical Trials (5)

NCT02842359Phase 4Completed

Evaluation of the Fixed-dose Combination of Irbesartan/Atorvastatin in Type 2 Diabetic Patients Diagnosed With Hyperlipidemia and Hypertension

Started Aug 2016
11 enrolled
Type 2 Diabetes Mellitus
NCT01625494Phase 3Completed

Study of Efficacy and Safety of Irbesartan/Amlodipine 4 Fixed Combination Therapy in Hypertensive Patients Uncontrolled on Irbesartan or Amlodipine Monotherapy

Started May 2012
158 enrolled
Hypertension
NCT00152698Phase 3Withdrawn

Effect of Irbesartan on Endothelial Function of the Retinal Vasculature in Patients With Hypercholesterolemia

Started Nov 2009
0
Hypercholesterolemia
NCT00956644Phase 3Completed

Irbesartan/Amlodipine in Hypertensive Patients Uncontrolled on Amlodipine 5 mg Monotherapy

Started Jul 2009
406 enrolled
Hypertension
NCT00950066Phase 2Completed

Irbesartan and Amlodipine Combination in Controlling Blood Pressure

Started Jul 2009
270 enrolled
Hypertension